Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
0.5299
USD
|
-2.91%
|
|
-20.91%
|
+3.33%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
891.9
|
1,626
|
1,393
|
311.2
|
52.27
|
63.81
|
-
|
-
|
Enterprise Value (EV)
1 |
632.8
|
1,125
|
1,022
|
68.24
|
0.3947
|
27.81
|
-24.33
|
10.21
|
P/E ratio
|
-2.9
x
|
-4.73
x
|
-4.34
x
|
-1.46
x
|
-0.2
x
|
-0.67
x
|
-1.53
x
|
-0.88
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
377%
|
377%
|
377%
|
Capitalization / Revenue
|
-
|
-
|
68.5
x
|
4.9
x
|
6.1
x
|
0.89
x
|
0.63
x
|
0.93
x
|
EV / Revenue
|
-
|
-
|
50.3
x
|
1.07
x
|
0.05
x
|
0.39
x
|
-0.24
x
|
0.15
x
|
EV / EBITDA
|
-2.19
x
|
-3.74
x
|
-3.09
x
|
-0.25
x
|
-0
x
|
-0.41
x
|
-0.86
x
|
-0.11
x
|
EV / FCF
|
-2.62
x
|
-6.07
x
|
-4.42
x
|
-0.25
x
|
-0
x
|
-0.7
x
|
0.32
x
|
-0.26
x
|
FCF Yield
|
-38.1%
|
-16.5%
|
-22.6%
|
-402%
|
-49,198%
|
-144%
|
312%
|
-392%
|
Price to Book
|
3.22
x
|
3.14
x
|
5.28
x
|
2.64
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
54,151
|
82,816
|
88,417
|
94,879
|
101,922
|
120,416
|
-
|
-
|
Reference price
2 |
16.47
|
19.63
|
15.76
|
3.280
|
0.5128
|
0.5299
|
0.5299
|
0.5299
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/28/22
|
2/8/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
20.34
|
63.57
|
8.573
|
71.67
|
101.2
|
68.34
|
EBITDA
1 |
-288.6
|
-300.7
|
-331.1
|
-274.9
|
-271.2
|
-67.76
|
28.33
|
-92.54
|
EBIT
1 |
-295.7
|
-309.1
|
-340.5
|
-280.5
|
-276
|
-127.6
|
-48.52
|
-87.09
|
Operating Margin
|
-
|
-
|
-1,673.85%
|
-441.25%
|
-3,219.48%
|
-177.99%
|
-47.93%
|
-127.42%
|
Earnings before Tax (EBT)
1 |
-291
|
-306.6
|
-340.1
|
-228.3
|
-276.1
|
-89
|
-50.25
|
-80.5
|
Net income
1 |
-291
|
-306.6
|
-340.1
|
-228.3
|
-276.1
|
-94.59
|
-48.22
|
-80.5
|
Net margin
|
-
|
-
|
-1,672.28%
|
-359.12%
|
-3,220.88%
|
-131.98%
|
-47.63%
|
-117.78%
|
EPS
2 |
-5.670
|
-4.150
|
-3.630
|
-2.240
|
-2.610
|
-0.7933
|
-0.3467
|
-0.6000
|
Free Cash Flow
1 |
-241.4
|
-185.3
|
-231.1
|
-274.6
|
-194.2
|
-40
|
-76
|
-40
|
FCF margin
|
-
|
-
|
-1,136.19%
|
-431.98%
|
-2,265.25%
|
-55.81%
|
-75.08%
|
-58.53%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
2.000
|
2.000
|
2.000
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/28/22
|
2/8/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
5.37
|
7.548
|
7.314
|
51.58
|
4.459
|
0.221
|
1.226
|
0.957
|
2.138
|
4.252
|
27.36
|
21.58
|
7.402
|
24.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-84.81
|
-93.4
|
-88.22
|
-32.13
|
-84.62
|
-75.54
|
-75.02
|
-71.41
|
-69.61
|
-59.96
|
-31.25
|
-18.78
|
-33.4
|
-8.2
|
Operating Margin
|
-1,579.37%
|
-1,237.45%
|
-1,206.18%
|
-62.3%
|
-1,897.78%
|
-34,180.54%
|
-6,118.92%
|
-7,462.28%
|
-3,255.94%
|
-1,410.21%
|
-114.22%
|
-87.04%
|
-451.23%
|
-33.88%
|
Earnings before Tax (EBT)
1 |
-84.66
|
-93.32
|
-88.1
|
18.47
|
-84.08
|
-74.57
|
-74.75
|
-71.11
|
-69.82
|
-60.44
|
-31.73
|
-15.5
|
-33.3
|
-8.05
|
Net income
1 |
-84.66
|
-93.35
|
-88.1
|
18.47
|
-84.09
|
-74.57
|
-74.77
|
-71.11
|
-69.8
|
-60.45
|
-31.75
|
-15.5
|
-33.3
|
-8.05
|
Net margin
|
-1,576.61%
|
-1,236.74%
|
-1,204.61%
|
35.8%
|
-1,885.87%
|
-33,742.99%
|
-6,098.78%
|
-7,430.3%
|
-3,264.59%
|
-1,421.68%
|
-116.07%
|
-71.84%
|
-449.88%
|
-33.26%
|
EPS
2 |
-0.9000
|
-0.9600
|
-0.8700
|
0.1800
|
-0.8200
|
-0.7200
|
-0.7200
|
-0.6800
|
-0.6600
|
-0.5600
|
-0.2300
|
-0.1300
|
-0.2450
|
-0.0750
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
2/28/22
|
5/5/22
|
8/8/22
|
11/8/22
|
2/8/23
|
5/8/23
|
8/8/23
|
11/1/23
|
3/28/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
259
|
501
|
371
|
243
|
51.9
|
36
|
88.1
|
53.6
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-241
|
-185
|
-231
|
-275
|
-194
|
-40
|
-76
|
-40
|
ROE (net income / shareholders' equity)
|
-92.4%
|
-81.4%
|
-91.7%
|
-54.1%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-79.2%
|
-65.9%
|
-64.4%
|
-112%
|
-
|
-
|
-
|
-
|
Assets
1 |
367.4
|
465.6
|
528.1
|
203.1
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
5.120
|
6.250
|
2.990
|
1.240
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
5.73
|
4.51
|
10.6
|
4.19
|
1.22
|
0.4
|
8
|
10
|
Capex / Sales
|
-
|
-
|
52.02%
|
6.6%
|
14.27%
|
0.56%
|
7.9%
|
14.63%
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/28/22
|
2/8/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
0.5299
USD Average target price
1.65
USD Spread / Average Target +211.38% Consensus |
1st Jan change
|
Capi.
|
---|
| +3.33% | 63.81M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|